Limits...
Nanocrystal technology, drug delivery and clinical applications.

Junghanns JU, Müller RH - Int J Nanomedicine (2008)

Bottom Line: The drug nanocrystals do not belong to the future; the first products are already on the market.The marketed products are presented and the special physical effects ofnanocrystals explained which are utilized in each market product.Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University of Berlin, Berlin, Germany. juj@junghanns.net

ABSTRACT
Nanotechnology will affect our lives tremendously over the next decade in very different fields, including medicine and pharmacy. Transfer of materials into the nanodimension changes their physical properties which were used in pharmaceutics to develop a new innovative formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do not belong to the future; the first products are already on the market. The industrially relevant production technologies, pearl milling and high pressure homogenization, are reviewed. The physics behind the drug nanocrystals and changes of their physical properties are discussed. The marketed products are presented and the special physical effects ofnanocrystals explained which are utilized in each market product. Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.

Show MeSH
Packaging of Tricor®.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2626933&req=5

f12-ijn-3-295: Packaging of Tricor®.

Mentions: Tricor® is being marketed by Abbott Laboratories and the active ingredient is fenofibrate, being available in 48 mg and 145 mg tablets (Figures 11, 12). Tricor is indicated as adjunctive therapy to diet in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb) to increase high-density lipoprotein cholesterol (HDL-C), reduce triglycerides (TG), reduce low-density lipoprotein cholesterol (LDL-C), reduce total cholesterol (Total-C), and reduce apolipoprotein B (Apo B).


Nanocrystal technology, drug delivery and clinical applications.

Junghanns JU, Müller RH - Int J Nanomedicine (2008)

Packaging of Tricor®.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2626933&req=5

f12-ijn-3-295: Packaging of Tricor®.
Mentions: Tricor® is being marketed by Abbott Laboratories and the active ingredient is fenofibrate, being available in 48 mg and 145 mg tablets (Figures 11, 12). Tricor is indicated as adjunctive therapy to diet in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb) to increase high-density lipoprotein cholesterol (HDL-C), reduce triglycerides (TG), reduce low-density lipoprotein cholesterol (LDL-C), reduce total cholesterol (Total-C), and reduce apolipoprotein B (Apo B).

Bottom Line: The drug nanocrystals do not belong to the future; the first products are already on the market.The marketed products are presented and the special physical effects ofnanocrystals explained which are utilized in each market product.Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmaceutical Technology, Biotechnology and Quality Management, Free University of Berlin, Berlin, Germany. juj@junghanns.net

ABSTRACT
Nanotechnology will affect our lives tremendously over the next decade in very different fields, including medicine and pharmacy. Transfer of materials into the nanodimension changes their physical properties which were used in pharmaceutics to develop a new innovative formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do not belong to the future; the first products are already on the market. The industrially relevant production technologies, pearl milling and high pressure homogenization, are reviewed. The physics behind the drug nanocrystals and changes of their physical properties are discussed. The marketed products are presented and the special physical effects ofnanocrystals explained which are utilized in each market product. Examples of products in the development pipelines (clinical phases) are presented and the benefits for in vivo administration of drug nanocrystals are summarized in an overview.

Show MeSH